Combinational spinal GAD65 gene delivery and systemic GABA-mimetic treatment for modulation of spasticity

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Kakinohana, Osamu ^a   Hefferan, Michael P ^a   Miyanohara, Atsushi ^a   Nejime, Tetsuya ^a   Marsala, Silvia ^a   Juhas, Stefan ^b   Juhasova, Jana ^b   Motlik, Jan ^b   Kucharova, Karolina ^c   Strnadel, Jan ^b   Platoshyn, Oleksandr ^a   Lazar, Peter ^d   Galik, Jan ^e,f   Vinay, Laurent ^g   Marsala, Martin ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF VETERINARY MEDICINE   (Slovakia)

^e INSTITUTE OF CHEMISTRY   (Slovakia)

^f P J AFÁRIK UNIVERSITY   (Slovakia)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE 65; LENTIVIRUS VECTOR; TIAGABINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; NEUROPROTECTIVE AGENT; NIPECOTIC ACID DERIVATIVE;

4 AMINOBUTYRIC ACID METABOLISM; 4 AMINOBUTYRIC ACID RELEASE; ADULT ANIMAL; ADVERSE OUTCOME; ALPHA NERVE FIBER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; EMBRYO; FETUS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; SPASTICITY; SYSTEMIC THERAPY; TREATMENT DURATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; EVALUATION; FEMALE; GENE THERAPY; GENETICS; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MINIPIG; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; SPINE; SPRAGUE DAWLEY RAT; SWINE;

ANIMALIA; LENTIVIRUS; RATTUS;

ANIMALS; ANTICONVULSANTS; CELLS, CULTURED; COMBINED MODALITY THERAPY; EMBRYO, MAMMALIAN; FEMALE; GABA AGONISTS; GENE EXPRESSION REGULATION; GENE THERAPY; GLUTAMATE DECARBOXYLASE; INJECTIONS, SPINAL; MALE; MUSCLE SPASTICITY; NEUROPROTECTIVE AGENTS; NIPECOTIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; SPINE; SWINE; SWINE, MINIATURE;

EID: 84856092665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030561     Document Type: Article

References (56)

1. Lance JW, Feldman RG, Young RR, Koella WP, (1980) Spasticity: Disordered motor control. (Symposium synopsis) Chicago Year Book Medical Publishers pp. 485-494.
2. Maurice V, Allan HR, Raymond DA, (2001) Adams & Victor's Principles of Neurology. McGraw-Hill Companies; 7-th edition.
3. Boulenguez P, Vinay L, (2009) Strategies to restore motor functions after spinal cord injury. Curr Opin Neurobiol 19: 587-600.
4. Li Y, Gorassini MA, Bennett DJ, (2004) Role of persistent sodium and calcium currents in motoneuron firing and spasticity in chronic spinal rats. J Neurophysiol 91: 767-783.
5. Marsala M, Hefferan MP, Kakinohana O, Nakamura S, Marsala J, et al. (2005) Measurement of peripheral muscle resistance in rats with chronic ischemia-induced paraplegia or morphine-induced rigidity using a semi-automated computer-controlled muscle resistance meter. J Neurotrauma 22: 1348-1361.
6. Siddall P, Xu CL, Cousins M, (1995) Allodynia following traumatic spinal cord injury in the rat. Neuroreport 6: 1241-1244.
7. Eide PK, Stubhaug A, Stenehjem AE, (1995) Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 37: 1080-1087.
8. Katz R, (1999) Presynaptic inhibition in humans: a comparison between normal and spastic patients. J Physiol Paris 93: 379-385.
9. Mazzocchio R, Rossi A, (1997) Involvement of spinal recurrent inhibition in spasticity. Further insight into the regulation of Renshaw cell activity. Brain 120 (Pt 6): 991-1003.
10. Boorman GI, Lee RG, Becker WJ, Windhorst UR, (1996) Impaired "natural reciprocal inhibition" in patients with spasticity due to incomplete spinal cord injury. Electroencephalogr Clin Neurophysiol 101: 84-92.
11. Remy-Neris O, Barbeau H, Daniel O, Boiteau F, Bussel B, (1999) Effects of intrathecal clonidine injection on spinal reflexes and human locomotion in incomplete paraplegic subjects. Exp Brain Res 129: 433-440.
12. Tillakaratne NJ, de Leon RD, Hoang TX, Roy RR, Edgerton VR, et al. (2002) Use-dependent modulation of inhibitory capacity in the feline lumbar spinal cord. J Neurosci 22: 3130-3143.
13. Ichiyama RM, Broman J, Roy RR, Zhong H, Edgerton VR, et al. (2011) Locomotor training maintains normal inhibitory influence on both alpha- and gamma-motoneurons after neonatal spinal cord transection. J Neurosci 31: 26-33.
14. Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, et al. (2010) Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med 16: 694-700.
15. Nielsen JF, Hansen HJ, Sunde N, Christensen JJ, (2002) Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg 104: 142-145.
16. Krach LE, (2001) Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 16: 31-36.
17. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R, Carillo JP, (1990) Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 72: 393-402.
18. Chu ML, Sala DA, (2006) The use of tiagabine in pediatric spasticity management. Dev Med Child Neurol 48: 456-459.
19. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, et al. (1992) The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 220: 197-201.
20. Dalby NO, (2000) GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39: 2399-2407.
21. Kakinohana O, Hefferan MP, Nakamura S, Kakinohana M, Galik J, et al. (2006) Development of gaba-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: A qualitative and quantitative electrophysiological and histopathological study. Neuroscience 141: 1569-1583.
22. Podrygajlo G, Song Y, Schlesinger F, Krampfl K, Bicker G, (2010) Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture. Neurosci Lett 468: 207-210.
23. Price TJ, Cervero F, de Koninck Y, (2005) Role of cation-chloride-cotransporters (CCC) in pain and hyperalgesia. Curr Top Med Chem 5: 547-555.
24. Maeda Y, Lisi TL, Vance CG, Sluka KA, (2007) Release of GABA and activation of GABA(A) in the spinal cord mediates the effects of TENS in rats. Brain Res 1136: 43-50.
25. Nowak LM, Young AB, Macdonald RL, (1982) GABA and bicuculline actions on mouse spinal cord and cortical neurons in cell culture. Brain Res 244: 155-164.
26. Schousboe A, Sarup A, Larsson OM, White HS, (2004) GABA transporters as drug targets for modulation of GABAergic activity. Biochem Pharmacol 68: 1557-1563.
27. Chaudhry FA, Reimer RJ, Bellocchio EE, Danbolt NC, Osen KK, et al. (1998) The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons. J Neurosci 18: 9733-9750.
28. Dachy B, Dan B, (2002) Electrophysiological assessment of the effect of intrathecal baclofen in spastic children. Clin Neurophysiol 113: 336-340.
29. Macdonell RA, Talalla A, Swash M, Grundy D, (1989) Intrathecal baclofen and the H-reflex. J Neurol Neurosurg Psychiatry 52: 1110-1112.
30. Tarlov IM, (1967) Rigidity in man due to spinal interneuron loss. Arch Neurol 16: 536-543.
31. Rosche J, (2002) Treatment of spasticity. Spinal Cord 40: 261-262.
32. Stempien L, Tsai T, (2000) Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 79: 536-541.
33. Jimenez I, Rudomin P, Enriquez M, (1991) Differential effects of (-)-baclofen on Ia and descending monosynaptic EPSPs. Exp Brain Res 85: 103-113.
34. Edwards FR, Harrison PJ, Jack JJ, Kullmann DM, (1989) Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetized cat. J Physiol 416: 539-556.
35. Krach LE, (2001) Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 16: 31-36.
36. Soni BM, Mani RM, Oo T, Vaidyanathan S, (2003) Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance-a case report and review of literature. Spinal Cord 41: 586-589.
37. Meythaler JM, Roper JF, Brunner RC, (2003) Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 84: 638-642.
38. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, et al. (2002) Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298: 425-429.
39. Wang X, Ratnaraj N, Patsalos PN, (2004) The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13: 574-581.
40. Brodie MJ, (1995) Tiagabine pharmacology in profile. Epilepsia 36 (Suppl 6): S7-S9.
41. Gustavson LE, Mengel HB, (1995) Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 36: 605-611.
42. Meunier A, Mauborgne A, Masson J, Mallet J, Pohl M, (2008) Lentiviral-mediated targeted transgene expression in dorsal spinal cord glia: tool for the study of glial cell implication in mechanisms underlying chronic pain development. J Neurosci Methods 167: 148-159.
43. Kornum BR, Stott SR, Mattsson B, Wisman L, Ettrup A, et al. (2010) Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Exp Neurol 222: 70-85.
44. McCarty DM, Young SM Jr, Samulski RJ, (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819-845.
45. Dodiya HB, Bjorklund T, Stansell J 3rd, Mandel RJ, Kirik D, et al. (2010) Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18: 579-587.
46. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, et al. (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317.
47. Taira Y, Marsala M, (1996) Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat. Stroke 27: 1850-1858.
48. Yaksh T, Rudy T, (1976) Chronic catheterization of the spinal subarachnoid space. PhysiolBehavior 17: 1031-1036.
49. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ, (1991) Two genes encode distinct glutamate decarboxylases. Neuron 7: 91-100.
50. Yam PY, Li S, Wu J, Hu J, Zaia JA, et al. (2002) Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 5: 479-484.
51. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, et al. (1994) A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A 91: 9564-9568.
52. Hartley RS, Margulis M, Fishman PS, Lee VM, Tang CM, (1999) Functional synapses are formed between human NTera2 (NT2N, hNT) neurons grown on astrocytes. Journal of Comparative Neurology 407: 1-10.
53. Kakinohana O, Cizkova D, Tomori Z, Hedlund E, Marsala S, et al. (2004) Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study. Exp Neurol 190: 122-132.
54. Usvald D, Vodicka P, Hlucilova J, Prochazka R, Motlik J, et al. (2010) Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant 19: 1103-1122.
55. Todd AJ, Hughes DI, Polgar E, Nagy GG, Mackie M, et al. (2003) The expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in neurochemically defined axonal populations in the rat spinal cord with emphasis on the dorsal horn. Eur J Neurosci 17: 13-27.
56. Hughes DI, Mackie M, Nagy GG, Riddell JS, Maxwell DJ, et al. (2005) P boutons in lamina IX of the rodent spinal cord express high levels of glutamic acid decarboxylase-65 and originate from cells in deep medial dorsal horn. PNAS 102: 9038-9043.